Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia
Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases. We evaluated...
Gespeichert in:
Veröffentlicht in: | Medical science monitor 2011-07, Vol.17 (7), p.CR376-CR380 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | CR380 |
---|---|
container_issue | 7 |
container_start_page | CR376 |
container_title | Medical science monitor |
container_volume | 17 |
creator | Kaya, Ali Uysal, Ismail Önder Güven, Ahmet Sami Engin, Aynur Gültürk, Abdulaziz İçağasıoğlu, Füsun Dilara Cevit, Ömer |
description | Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases.
We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection.
We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions ( |
doi_str_mv | 10.12659/MSM.881848 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3539565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>874186825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-66160e7d69d810757300b35b5faba6982a5b672a963ad15a418011e65210c9733</originalsourceid><addsrcrecordid>eNpVUU1Lw0AQXUSxtXryLrl5kNT9yH7kIkjxC1oEredlkmzalXy5myj-e1dbi8LAzDCP9x7zEDoleEqo4Onl4nkxVYqoRO2hMREJi5nkeD_MlCUxwQSP0JH3rxhTJTA_RCNKJE4FI2P0tHQG-to0fVSCrQZnoraMVmGH2ua2iUJ1prDQO5tHHfQ2nHz0Yft11Lq2W4P7bFYGqqgfKnCmtnCMDkqovDnZ9gl6ub1Zzu7j-ePdw-x6HudM4T4WgghsZCHSQhEsuWQYZ4xnvIQMRKoo8ExICsEnFIRDQhQmxAhOCc5TydgEXW14uyGrTZEHYw4q3TlbB1O6Bav_Xxq71qv2XTPOUi54IDjfErj2bTC-17X1uakqaEw7eK1k0BSKfiMvNsjctd47U-5UCNY_IegQgt6EENBnf43tsL9fZ1-0h4Mo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>874186825</pqid></control><display><type>article</type><title>Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Kaya, Ali ; Uysal, Ismail Önder ; Güven, Ahmet Sami ; Engin, Aynur ; Gültürk, Abdulaziz ; İçağasıoğlu, Füsun Dilara ; Cevit, Ömer</creator><creatorcontrib>Kaya, Ali ; Uysal, Ismail Önder ; Güven, Ahmet Sami ; Engin, Aynur ; Gültürk, Abdulaziz ; İçağasıoğlu, Füsun Dilara ; Cevit, Ömer</creatorcontrib><description>Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases.
We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection.
We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions (<1 cm).
All patients were first treated with gentamicin, but were than given streptomycin after failure of gentamicin. This treatment was successful in all patients. The results of our study suggest that streptomycin is an effective choice of first-line treatment for pediatric oropharyngeal tularemia patients.</description><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.881848</identifier><identifier>PMID: 21709631</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Adolescent ; Child ; Clinical Research ; Female ; Gentamicins - therapeutic use ; Humans ; Lymph Nodes - pathology ; Male ; Retrospective Studies ; Streptomycin - therapeutic use ; Treatment Failure ; Tularemia - drug therapy ; Tularemia - pathology ; Turkey</subject><ispartof>Medical science monitor, 2011-07, Vol.17 (7), p.CR376-CR380</ispartof><rights>Med Sci Monit, 2011 2011</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-66160e7d69d810757300b35b5faba6982a5b672a963ad15a418011e65210c9733</citedby><cites>FETCH-LOGICAL-c380t-66160e7d69d810757300b35b5faba6982a5b672a963ad15a418011e65210c9733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539565/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539565/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21709631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaya, Ali</creatorcontrib><creatorcontrib>Uysal, Ismail Önder</creatorcontrib><creatorcontrib>Güven, Ahmet Sami</creatorcontrib><creatorcontrib>Engin, Aynur</creatorcontrib><creatorcontrib>Gültürk, Abdulaziz</creatorcontrib><creatorcontrib>İçağasıoğlu, Füsun Dilara</creatorcontrib><creatorcontrib>Cevit, Ömer</creatorcontrib><title>Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases.
We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection.
We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions (<1 cm).
All patients were first treated with gentamicin, but were than given streptomycin after failure of gentamicin. This treatment was successful in all patients. The results of our study suggest that streptomycin is an effective choice of first-line treatment for pediatric oropharyngeal tularemia patients.</description><subject>Adolescent</subject><subject>Child</subject><subject>Clinical Research</subject><subject>Female</subject><subject>Gentamicins - therapeutic use</subject><subject>Humans</subject><subject>Lymph Nodes - pathology</subject><subject>Male</subject><subject>Retrospective Studies</subject><subject>Streptomycin - therapeutic use</subject><subject>Treatment Failure</subject><subject>Tularemia - drug therapy</subject><subject>Tularemia - pathology</subject><subject>Turkey</subject><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1Lw0AQXUSxtXryLrl5kNT9yH7kIkjxC1oEredlkmzalXy5myj-e1dbi8LAzDCP9x7zEDoleEqo4Onl4nkxVYqoRO2hMREJi5nkeD_MlCUxwQSP0JH3rxhTJTA_RCNKJE4FI2P0tHQG-to0fVSCrQZnoraMVmGH2ua2iUJ1prDQO5tHHfQ2nHz0Yft11Lq2W4P7bFYGqqgfKnCmtnCMDkqovDnZ9gl6ub1Zzu7j-ePdw-x6HudM4T4WgghsZCHSQhEsuWQYZ4xnvIQMRKoo8ExICsEnFIRDQhQmxAhOCc5TydgEXW14uyGrTZEHYw4q3TlbB1O6Bav_Xxq71qv2XTPOUi54IDjfErj2bTC-17X1uakqaEw7eK1k0BSKfiMvNsjctd47U-5UCNY_IegQgt6EENBnf43tsL9fZ1-0h4Mo</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Kaya, Ali</creator><creator>Uysal, Ismail Önder</creator><creator>Güven, Ahmet Sami</creator><creator>Engin, Aynur</creator><creator>Gültürk, Abdulaziz</creator><creator>İçağasıoğlu, Füsun Dilara</creator><creator>Cevit, Ömer</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110701</creationdate><title>Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia</title><author>Kaya, Ali ; Uysal, Ismail Önder ; Güven, Ahmet Sami ; Engin, Aynur ; Gültürk, Abdulaziz ; İçağasıoğlu, Füsun Dilara ; Cevit, Ömer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-66160e7d69d810757300b35b5faba6982a5b672a963ad15a418011e65210c9733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Child</topic><topic>Clinical Research</topic><topic>Female</topic><topic>Gentamicins - therapeutic use</topic><topic>Humans</topic><topic>Lymph Nodes - pathology</topic><topic>Male</topic><topic>Retrospective Studies</topic><topic>Streptomycin - therapeutic use</topic><topic>Treatment Failure</topic><topic>Tularemia - drug therapy</topic><topic>Tularemia - pathology</topic><topic>Turkey</topic><toplevel>online_resources</toplevel><creatorcontrib>Kaya, Ali</creatorcontrib><creatorcontrib>Uysal, Ismail Önder</creatorcontrib><creatorcontrib>Güven, Ahmet Sami</creatorcontrib><creatorcontrib>Engin, Aynur</creatorcontrib><creatorcontrib>Gültürk, Abdulaziz</creatorcontrib><creatorcontrib>İçağasıoğlu, Füsun Dilara</creatorcontrib><creatorcontrib>Cevit, Ömer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaya, Ali</au><au>Uysal, Ismail Önder</au><au>Güven, Ahmet Sami</au><au>Engin, Aynur</au><au>Gültürk, Abdulaziz</au><au>İçağasıoğlu, Füsun Dilara</au><au>Cevit, Ömer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>17</volume><issue>7</issue><spage>CR376</spage><epage>CR380</epage><pages>CR376-CR380</pages><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases.
We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection.
We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions (<1 cm).
All patients were first treated with gentamicin, but were than given streptomycin after failure of gentamicin. This treatment was successful in all patients. The results of our study suggest that streptomycin is an effective choice of first-line treatment for pediatric oropharyngeal tularemia patients.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>21709631</pmid><doi>10.12659/MSM.881848</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1234-1010 |
ispartof | Medical science monitor, 2011-07, Vol.17 (7), p.CR376-CR380 |
issn | 1234-1010 1643-3750 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3539565 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
subjects | Adolescent Child Clinical Research Female Gentamicins - therapeutic use Humans Lymph Nodes - pathology Male Retrospective Studies Streptomycin - therapeutic use Treatment Failure Tularemia - drug therapy Tularemia - pathology Turkey |
title | Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T18%3A21%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20failure%20of%20gentamicin%20in%20pediatric%20patients%20with%20oropharyngeal%20tularemia&rft.jtitle=Medical%20science%20monitor&rft.au=Kaya,%20Ali&rft.date=2011-07-01&rft.volume=17&rft.issue=7&rft.spage=CR376&rft.epage=CR380&rft.pages=CR376-CR380&rft.issn=1234-1010&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.881848&rft_dat=%3Cproquest_pubme%3E874186825%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=874186825&rft_id=info:pmid/21709631&rfr_iscdi=true |